Musclepharm's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Musclepharm (MSLP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Musclepharm vs Its Competitors
- TTM: Trailing 12-month revenue of 50M vs 22M combined for tracked competitors (69.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+4.8% annualized vs trailing 12 months), vs accelerating (+207.5%) for its tracked peer group.
- Growth: Musclepharm generated -0.2% revenue growth year over year in Q1 2022, vs 57.1% for its tracked competitors combined.
- Profitability: Its -48.1% net margin compares with -23.8% for the peer group.
- Peer revenue share: Musclepharm accounted for 43.5% of combined revenue among its tracked peer group, down from 54.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.20M compares with $2.01M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MSLP Sales vs. its Competitors, Q1 2022
Musclepharm reported revenue contraction of 0.15 % year on year in Q1 2022, below its competitors' combined revenue growth of 57.10 %.
With a net margin of -48.10 %, Musclepharm reported lower profitability than its competitors (-23.75 %).
Musclepharm generated 43.50 % of the combined sales of its peer group, down from 54.78 % a year earlier.
Musclepharm vs. its Competitors, Q1 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Musclepharm and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Musclepharm Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Musclepharm's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -0.2% for Musclepharm. Musclepharm's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Musclepharm's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Musclepharm Corporation | No | No | No | Yes |
| Competitors combined (1) | ||||
| High-Confidence Competitors (2) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MSLP Stock Performance relative to its Competitors
MSLP Stock Performance relative to High-Confidence Competitors
MSLP Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Srx Health Solutions Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Musclepharm's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Musclepharm's Comment on Competition and Industry Peers
Our range of competitors includes numerous nutritional supplement companies that are highly fragmented in terms of geographic market coverage, distribution channels and product categories. In addition, large pharmaceutical companies and packaged food and beverage companies compete with us in the nutritional supplement market. Many of these companies have greater financial and distribution resources available to them than MusclePharm and many of these companies compete through vertical integration. Private label entities have gained a foothold in many nutrition categories and also are direct competitors. A few of these are private label entities have become market leaders. Our principal competitors are Optimum Nutrition, Inc., Cellucor, and Quest Nutrition, LLC.
In this industry, most of the companies are privately held. With respect to retailer sales, we cannot fully gauge their sizes and our relative ranking. We believe that retailers look to partner with suppliers who demonstrate brand awareness, market intelligence, customer service and science. We believe we are competitive in all of these areas.
Publicly Traded Peers of Musclepharm Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Musclepharm Corporation | 0.20 | 50.02 |
| Srx Health Solutions Inc | 18.04 | 22.13 |
| SUBTOTAL | 18.25 | 72.15 |
Sources: Musclepharm Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Musclepharm Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Musclepharm's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Fitlife Brands Inc | Named by the company | 85% |
| Nutrabolt | Named by the company | 85% |
| Glanbia Performance Nutrition | Named by the company | 85% |
| Celsius | Named by the company | 85% |
| Iovate Health Sciences International Inc. | Named by the company | 85% |
| Dymatize Enterprises LLC | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Musclepharm's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Musclepharm's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Srx Health Solutions Inc | Health Solutions 0.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Musclepharm's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Musclepharm Corporation | 0 | 201,702 | -77,665 |
| Srx Health Solutions Inc | 18 | 2,011,818 | -4,352,364 |
| PEERS TOTAL | 18 | 2,011,818 | -4,352,364 |
Musclepharm's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Musclepharm Corporation | Food Drug and Mass 68.58 % |
| Srx Health Solutions Inc | US 89.62 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Musclepharm's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 6.38 % | 64.89 % (avg) | -58.5 pp |
| Operating Margin | -23.32 % | industry median | +240.7 pp |
| EBITDA Margin | -25.22 % | -7.21 % (avg) | -18.0 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.92 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Musclepharm's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.3x | 4.5x | -4.8x |
| Return on Equity | 60.99 % | industry aggregate | 41.93 % |
| Return on Invested Capital | 19.38 % | -2.95 % (avg) | 22.33 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Musclepharm's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 65.35 % | 59.99 % | -5.94 % | -20.59 % | -22.90 % | -25.26 % | -19.11 % | -22.34 % |
| Operating Margin | -12.89 % | -10.92 % | -29.93 % | -6.53 % | -7.04 % | -18.96 % | 4.04 % | -17.81 % |
| Return on Invested Capital | -45.91 % | -29.04 % | -253.83 % | 45.76 % | 70.09 % | 25.76 % | -5.10 % | 16.94 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Musclepharm's Strategic Group Map
Every company in Musclepharm's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Musclepharm is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Musclepharm's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Musclepharm's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Musclepharm's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Musclepharm's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Musclepharm falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Musclepharm's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 240.7 points above the industry median.
- Return on equity 41.9 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+4.8% annualized vs trailing 12 months).
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Musclepharm's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Musclepharm Corporation | 0.02 | 0.28 | - |
| Srx Health Solutions Inc | 1.99 | 4.17 | 0.15 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Musclepharm's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Musclepharm Corporation | Q1 2022 | -0.2 % | - |
| Srx Health Solutions Inc | Q2 2026 | -70.3 % | - |
| PEERS TOTAL | -32.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Musclepharm's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Musclepharm Corporation | Q1 2022 | +22.9 % | - |
| Srx Health Solutions Inc | Q2 2026 | -5.8 % | - |
Musclepharm's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Musclepharm Corporation | - | - | - |
| Srx Health Solutions Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Musclepharm's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Musclepharm Corporation | - | 0.00 |
| Srx Health Solutions Inc | - | 0.82 |
| PEERS AVERAGE | - | 0.25 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.